EUVIMEDEUVIMED entdecken
Open Access

Cardiac Gene Therapy With Phosphodiesterase 2A Limits Remodeling and Arrhythmias in Mouse Models of Heart Failure

Rima Kamel, Aurélia Bourcier iD, Jean Piero Margaria, Valentin Jin, Audrey Varin iD, Agnès Hivonnait iD, Françoise Mercier-Nomé iD, Delphine Mika iD, Alessandra Ghigo iD, Flavien Charpentier iD, Vincent Algalarrondo iD, Emilio Hirsch iD und 3 weitere

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.037343 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Rima Kamel und 14 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Saclay, Inserm, Signaling and Cardiovascular Pathophysiology, UMR-S 1180 Orsay France. Hauptthemen laut MEDLINE: Heart Failure, Genetic Therapy, Ventricular Remodeling, Arrhythmias, Cardiac. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

PDE2 (phosphodiesterase 2) is upregulated in human heart failure. Cardiac PDE2‐transgenic mice are protected against contractile dysfunction and arrhythmias in heart failure but whether an acute elevation of PDE2 could be of therapeutic value remains elusive. This hypothesis was tested using cardiac PDE2 gene transfer in preclinical models of heart failure. Methods and Results C57BL/6 male mice were injected with serotype 9 adeno‐associated viruses encoding for PDE2A. This led to a ≈10‐fold rise of PDE2A protein levels that affected neither cardiac structure nor function in healthy mice. Two weeks after inoculation with serotype 9 adeno‐associated viruses, mice were implanted with minipumps delivering either NaCl, isoproterenol (60 mg/kg per day), or isoproterenol and phenylephrine (30 mg/kg per day each) for 2 weeks. In mice injected with serotype 9 adeno‐associated viruses encoding for LUC (luciferase), isoproterenol or isoproterenol+phenylephrine infusion induced left ventricular hypertrophy, decreased ejection fraction unveiled by echocardiography, and promoted fibrosis and apoptosis assessed by Masson's trichrome and Tunel, respectively. Furthermore, inotropic responses to isoproterenol of ventricular cardiomyocytes isolated from isoproterenol+phenylephrine‐LUC mice loaded with 1 μmol/L Fura‐2AM and stimulated at 1 Hz to record calcium transients and sarcomere shortening were dampened. Spontaneous calcium waves at the cellular level were promoted as well as ventricular arrhythmias evoked in vivo by catheter‐mediated ventricular pacing after isoproterenol (1.5 mg/kg) and atropine (1 mg/kg) injection. However, increased PDE2A blunted these adverse outcomes evoked by sympathomimetic amines.

Conclusions

Cardiac gene therapy with PDE2A limits left ventricle remodeling, dysfunction, and arrhythmias evoked by catecholamines, providing evidence that increasing PDE2A activity acutely could prevent progression toward heart failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureGenetic TherapyVentricular RemodelingArrhythmias, CardiacCyclic Nucleotide Phosphodiesterases, Type 2AnimalsDisease Models, AnimalMice, Inbred C57BLMaleMyocytes, CardiacDependovirusMiceHypertrophy, Left VentricularIsoproterenolApoptosisVentricular Function, LeftFibrosis

Stichwörter der Autor:innen

arrhythmiacAMP‐phosphodiesterasecatecholaminesexcitation‐contraction couplinggene therapyheart failure

Substanzen

Cyclic Nucleotide Phosphodiesterases, Type 2Pde2a protein, mouseIsoproterenol

Autor:innen und Institutionen

  • Université Paris-Saclay, Inserm, Signaling and Cardiovascular Pathophysiology, UMR-S 1180 Orsay France.
  • Molecular Biotechnology Center "Guido Tarone", Department of Molecular Biotechnology and Health Sciences University of Torino Italy.
  • Cystic Kidney Disorders Unit, Division of Genetics and Cell Biology Università Vita-Salute San Raffaele Milan Italy.
  • Nantes Université, CNRS, INSERM, l'institut du thorax Nantes France.
  • Université Paris-Saclay, Inserm US31, CNRS UMS3679, IPSIT Orsay France.

ORCID-Profile: Aurélia Bourcier, Audrey Varin, Agnès Hivonnait, Françoise Mercier-Nomé, Delphine Mika, Alessandra Ghigo, Flavien Charpentier, Vincent Algalarrondo, Emilio Hirsch, Rodolphe Fischmeister, Grégoire Vandecasteele, Jérôme Leroy

Zitieren

APA

Kamel, R., Bourcier, A., Margaria, J. P., Jin, V., Varin, A., Hivonnait, A., Mercier-Nomé, F., Mika, D., Ghigo, A., Charpentier, F., Algalarrondo, V., Hirsch, E., Fischmeister, R., Vandecasteele, G., & Leroy, J. (2025). Cardiac Gene Therapy With Phosphodiesterase 2A Limits Remodeling and Arrhythmias in Mouse Models of Heart Failure. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.037343

Vancouver

Kamel R, Bourcier A, Margaria JP, Jin V, Varin A, Hivonnait A, et al. Cardiac Gene Therapy With Phosphodiesterase 2A Limits Remodeling and Arrhythmias in Mouse Models of Heart Failure. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.037343

BibTeX
@article{Kamel2025,
  author = {Kamel, Rima and Bourcier, Aurélia and Margaria, Jean Piero and Jin, Valentin and Varin, Audrey and Hivonnait, Agnès and Mercier-Nomé, Françoise and Mika, Delphine and Ghigo, Alessandra and Charpentier, Flavien and Algalarrondo, Vincent and Hirsch, Emilio and Fischmeister, Rodolphe and Vandecasteele, Grégoire and Leroy, Jérôme},
  title = {Cardiac Gene Therapy With Phosphodiesterase 2A Limits Remodeling and Arrhythmias in Mouse Models of Heart Failure},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.037343}
}
Kostenlos starten →